• Empower Clinics (CBDT) subsidiary Medisure has announced the launch of the Vitamin D Rapid Testing Kit
  • Chairman & CEO Steven McAuley sat down with Shoran Devi to discuss the news
  • The MediSure® Vitamin D Rapid Test Kits will be available at local PharmaChoice® pharmacies across the country beginning in May
  • Empower is an integrated healthcare company that provides digital and telemedicine care
  • Empower Clinics Inc. (CBDT) opened trading at C$0.125 per share

Empower Clinics (CBDT) subsidiary Medisure has announced the launch of the Vitamin D Rapid Testing Kit.

Steven McAuley, Chairman and CEO of Empower Clinics sat down with Shoran Devi to discuss the news.

“The launch and pre-sales of this Vitamin D at-home testing solution is a perfect execution of our vision of being a leading integrated healthcare company.

We co-created this product in partnership with pharmacies who in turn placed advance orders. We maximized internal synergies by distributing this Medisure product to our Medi-Collective (TMC) clinics. And we are delivering on our commitment to continually offer convenient, accessible and integrated healthcare solutions – online, in our TMC clinics or in our partner pharmacies – to patients across Canada.”

The MediSure® Vitamin D Rapid Test Kits will be available at local PharmaChoice® pharmacies across the country beginning in May.

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, a medical device company and world-class medical diagnostics laboratories. Empower is aggressively growing its clinical and digital presence across North America.

Empower Clinics Inc. (CBDT) opened trading at C$0.125 per share.

 

More From The Market Online

@ the Bell: Despite a deep divide, the TSX comes out on top

Canada’s main stock index was volatile Thursday, but thanks to an industrials, utilities and energy market surge, the TSX closed in the green.

A promising player in the energy revolution

As demand for sustainable energy sources has intensified, Argentina Lithium & Energy is ready to capitalize on the surging lithium market.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

Fobi AI could address a market in the trillions: Why it’s time to buy

Fobi AI (TSXV:FOBI) is an essential stock to consider to capitalize on the exponential trends of digital wallets and artificial intelligence.